Most importantly, if the pathologist overestimates the tumor burden (Figure 1A–C) and macrodissection is consequently left undone, the risk of false-negative results increases, which may leave a melanoma patient without the potential advantages of BRAF or MEK inhibitors. The gene discussed is BRAF; the disease is melanoma.